Genetic approaches have advanced the understanding of biological pathways underlying inter-individual variation in BP. For example, studies of rare Mendelian BP disorders have identified multiple defects in renal sodium handling pathways^[@R4]^. More recently two genome-wide association studies (GWAS), each of \>25,000 individuals of European-ancestry, identified 13 loci associated with SBP, DBP, and hypertension^[@R5],[@R6]^. We now report results of a new meta-analysis of GWAS data that includes staged follow-up genotyping to identify additional BP loci.

Primary analyses evaluated associations between 2.5 million genotyped or imputed single nucleotide polymorphisms (SNPs) and SBP and DBP in 69,395 individuals of European ancestry from 29 studies (Supplementary Materials Sections 1--3, Supplementary Tables 1--2). Following GWAS meta-analysis, we conducted a three-stage validation experiment that made efficient use of available genotyping resources, to follow up top signals in up to 133,661 additional individuals of European descent ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"} and [Supplementary Materials Section 4](#SD1){ref-type="supplementary-material"}). Twenty-nine independent SNPs at 28 loci were significantly associated with SBP, DBP, or both in the meta-analysis combining discovery and follow up data ([Fig. 1](#F1){ref-type="fig"}, [Table 1](#T1){ref-type="table"}, [Supplementary Figs 2--3](#SD1){ref-type="supplementary-material"}, [Supplementary Tables 3--5](#SD1){ref-type="supplementary-material"}). All 29 SNPs attained association *P* \<5×10^−9^, an order of magnitude beyond the standard genome-wide significance level for a single stage experiment ([Table 1](#T1){ref-type="table"}).

Sixteen of these 29 associations were novel ([Table 1](#T1){ref-type="table"}). Two associations were near the *FURIN* and *GOSR2* genes; prior targeted analyses of variants in these genes suggested they may be BP loci^[@R7],[@R8]^. At the *CACNB2* locus we validated association for a previously reported^[@R6]^ SNP rs4373814 and detected a novel independent association for rs1813353 (pairwise r^2^ =0.015 in HapMap CEU). Of our 13 previously reported associations^[@R5],[@R6]^, only the association at *PLCD3* was not supported by the current results ([Supplementary Table 4](#SD1){ref-type="supplementary-material"}). Some of the associations are in or near genes involved in pathways known to influence BP (*NPR3*, *GUCY1A3-GUCY1B3*, *ADM*, *GNAS-EDN3, NPPA-NPPB,* and *CYP17A1;* [Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}). Twenty-two of the 28 loci did not contain genes that were *a priori* strong biological candidates.

As expected from prior BP GWAS results, the effects of the novel variants on SBP and DBP were small ([Fig. 1](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). For all variants, the observed directions of effects were concordant for SBP, DBP, and hypertension ([Fig. 1](#F1){ref-type="fig"}, [Table 1](#T1){ref-type="table"}, [Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}). Among the genes at the genome-wide significant loci, only *CYP17A1*, previously implicated in Mendelian congenital adrenal hyperplasia and hypertension, is known to harbour rare variants that have large effects on BP^[@R9]^.

We performed several analyses to identify potential causal alleles and mechanisms. First, we looked up the 29 genome-wide significant index SNPs and their close proxies (r^2^\>0.8) among *cis*-acting expression SNP (eSNP) results from multiple tissues ([Supplementary Materials Section 5](#SD1){ref-type="supplementary-material"}). For 13/29 index SNPs, we found association between nearby eSNP variants and expression level of at least one gene transcript (10^−4^ \> p \> 10^−51^, [Supplementary Table 6](#SD1){ref-type="supplementary-material"}). In 5 cases, the index BP SNP and the best eSNP from a genome-wide survey were identical, highlighting potential mediators of the SNP-BP associations.

Second, because changes in protein sequence are strong *a priori* candidates to be functional, we sought non-synonymous coding SNPs that were in high LD (r^2^ \>0.8) with the 29 index SNPs. We identified such SNPsat 8 loci ([Table 1](#T1){ref-type="table"}, [Supplementary Materials Section 6](#SD1){ref-type="supplementary-material"}, [Supplementary Table 7](#SD1){ref-type="supplementary-material"}). In addition we performed analyses testing for differences in genetic effect according to body mass index (BMI) or sex, and analyses of copy number variants, pathway enrichment, and metabolomic data, but we did not find any statistically significant results ([Supplementary Materials Sections 7--9](#SD1){ref-type="supplementary-material"}, [Supplementary Tables 8--10](#SD1){ref-type="supplementary-material"}).

We evaluated whether the BP variants we identified in Europeans were associated with BP in individuals of East Asian (N=29,719), South Asian (N=23,977), and African (N=19,775) ancestries ([Table 1](#T1){ref-type="table"}, [Supplementary Tables 11--13](#SD1){ref-type="supplementary-material"}). We found significant associations in individuals of East Asian ancestry for SNPs at 9 loci and in individuals of South Asian ancestry for SNPs at 6 loci; some have been reported previously ([Supplementary Tables 12 and 15](#SD1){ref-type="supplementary-material"}). The lack of significant association for individual SNPs may reflect small sample sizes, differences in allele frequencies or LD patterns, imprecise imputation for some ancestries using existing reference samples, or a genuinely different underlying genetic architecture. Because of limited power to detect effects of individual variants in the smaller non-European samples, we created genetic risk scores for SBP and DBP incorporating all 29 BP variants weighted according to effect sizes observed in the European samples. In each non-European ancestry group, risk scores were strongly associated with SBP (*P*=1.1×10^−40^ in East Asian, *P*=2.9×10^−13^ in South Asian, *P*=9.8×10^−4^ in African ancestry individuals) and DBP (*P*=2.9×10^−48^, *P*=9.5×10^−15^, and *P*=5.3×10^−5^, respectively; [Supplementary Table 13](#SD1){ref-type="supplementary-material"}).

We also created a genetic risk score to assess association of the variants in aggregate with hypertension and with clinical measures of hypertensive complications including left ventricular mass, left ventricular wall thickness, incident heart failure, incident and prevalent stroke, prevalent coronary artery disease (CAD), kidney disease, and measures of kidney function, using results from other GWAS consortia ([Table 2](#T2){ref-type="table"}, [Supplementary Materials Sections 10--11](#SD1){ref-type="supplementary-material"}, [Supplementary Table 14](#SD1){ref-type="supplementary-material"}). The risk score was weighted using the average of SBP and DBP effects for the 29 SNPs. In an independent sample of 23,294 women^[@R10]^, an increase of 1 standard deviation in the genetic risk score was associated with a 21% increase in the odds of hypertension (95% CI 19%--28%; [Table 2](#T2){ref-type="table"}, [Supplementary Table 14](#SD1){ref-type="supplementary-material"}). Among individuals in the top decile of the risk score, the prevalence of hypertension was 29% compared with 16% in the bottom decile (odds ratio 2.09, 95% CI 1.86--2.36). Similar results were observed in an independent hypertension case-control sample ([Table 2](#T2){ref-type="table"}). In our study, individuals in the top compared to bottom quintiles of genetic risk score differed by 4.6 mm Hg SBP and 3.0 mm Hg DBP, differences that approach population-averaged BP treatment effects for a single antihypertensive agent^[@R11]^. Epidemiologic data have shown that differences in SBP and DBP of this magnitude, across the population range of BP, are associated with an increase in cardiovascular disease risk^[@R3]^. Consistent with this and in line with findings from randomized trials of BP-lowering medication in hypertensive patients^[@R12],[@R13]^, the genetic risk score was positively associated with left ventricular wall thickness (*P*=6.0×10^−6^), occurrence of stroke (*P*=3.3×10^−5^) and CAD (*P*=8.1×10^−29^). The same genetic risk score was not, however, significantly associated with chronic kidney disease or measures of kidney function, even though these renal outcomes were available in a similar sample size as for the other outcomes ([Table 2](#T2){ref-type="table"}). The absence of association with kidney phenotypes could be explained by a weaker causal relation of BP with kidney phenotypes than with CAD and stroke. This finding is consistent with the mismatch between observational data that show a positive association of BP with kidney disease, and clinical trial data that show inconsistent evidence of benefit of BP lowering on kidney disease prevention in patients with hypertension^[@R14]^. Thus, several lines of evidence converge to suggest that BP elevation may in part be a consequence rather than a cause of sub-clinical kidney disease.

Our discovery meta-analysis ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}) suggests an excess of modestly significant (10^−5^ \<*P* \<10^−2^) associations likely arising from common BP variants of small effect. By dividing our principal GWAS dataset into non-overlapping discovery (N≈56,000) and validation (N≈14,000) subsets, we found robust evidence for the existence of such undetected common variants ([Supplementary Fig. 5](#SD1){ref-type="supplementary-material"}, [Supplementary Materials Section 12](#SD1){ref-type="supplementary-material"}). We estimate^[@R15]^ that there are 116 (95% CI 57--174) independent BP variants with effect sizes similar to those reported here, which collectively explain ≈2.2% of the phenotypic variance for SBP and DBP, compared with 0.9% explained by the 29 associations discovered thus far ([Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}, [Supplementary Materials Section 13](#SD1){ref-type="supplementary-material"}).

Most of the 28 BP loci harbour multiple genes ([Supplementary Table 15](#SD1){ref-type="supplementary-material"}, [Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}), and although substantial research is required to identify the specific genes and variants responsible for these associations, several loci contain highly plausible biological candidates. The *NPPA* and *NPPB* genes at the *MTHFR*-*NPPB* locus encode precursors for atrial- and B-type natriuretic peptides (ANP, BNP), and previous work has identified SNPs, modestly correlated with our index SNP at this locus, that are associated with plasma ANP, BNP, and BP^[@R16]^. We found the index SNP at this locus was associated with opposite effects on BP and on ANP/BNP levels, consistent with a model in which the variants act through increased ANP/BNP production to lower BP^[@R16]^ ([Supplementary Materials Section 14](#SD1){ref-type="supplementary-material"}).

Two other loci identified in the current study harbour genes involved in natriuretic peptide and related nitric oxide signalling pathways,^[@R17],[@R18]^ both of which act to regulate cyclic guanosine monophosphate (cGMP). The first locus contains *NPR3,* which encodes the natriuretic peptide clearance receptor (NPR-C). *NPR3* knockout mice exhibit reduced clearance of circulating natriuretic peptides and lower BP^[@R19]^. The second locus includes *GUCY1A3* and *GUCY1B3,* encoding the alpha and beta subunits of soluble guanylatecyclase (sGC); knockout of either gene in murine models results in hypertension^[@R20]^.

Another locus contains *ADM*, encoding adrenomedullin, which has natriuretic, vasodilatory, and BP-lowering properties^[@R21]^. At the *GNAS*-*EDN3* locus, *ZNF831* is closest to the index SNP*,* but *GNAS* and *EDN3* are two nearby compelling biological candidates ([Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}, [Supplementary Table 15](#SD1){ref-type="supplementary-material"}).

We identified two loci with plausible connections to BP via genes implicated in renal physiology or kidney disease. At the first locus, *SLC4A7* is an electro-neutral sodium bicarbonate co-transporter expressed in the nephron and in vascular smooth muscle^[@R22]^. At the second locus, *PLCE1* (phospholipase-C-epsilon-1 isoform) is important for normal podocyte development in the glomerulus; sequence variation in *PLCE1* has been implicated in familial nephrotic syndromes and end-stage kidney disease^[@R23]^.

Missense variants in two genes involved in metal ion transport were associated with BP in our study. The first encodes a His/Asp change at amino acid 63 (*H63D)* in *HFE* and is a low penetrance allele for hereditary hemochromatosis^[@R24]^. The second is an Ala/Thr polymorphism located in exon 7 of *SLC39A8*, which encodes a zinc transporter that also transports cadmium and manganese^[@R25]^. The same allele of *SLC39A8* associated with BP in our study has recently been associated with high-density lipoprotein (HDL) cholesterol levels^[@R26]^ and BMI^[@R27]^ ([Supplementary Table 15](#SD1){ref-type="supplementary-material"}).

In conclusion, we have shown that 29 independent genetic variants influence BP in people of European ancestry. The variants reside in 28 loci, 16 of which were novel, and we confirmed association of several of them in individuals of non-European ancestry. A risk score derived from the 29 variants was significantly associated with BP-related organ damage and clinical cardiovascular disease, but not kidney disease. These loci improve our understanding of the genetic architecture of BP, provide new biological insights into BP control and may identify novel targets for the treatment of hypertension and the prevention of cardiovascular disease.

Methods summary {#S1}
===============

[Supplementary Materials](#SD1){ref-type="supplementary-material"} provide complete methods and include the following sections: study recruitment and phenotyping, adjustment for antihypertensive medications, genotyping, data quality control, genotype imputation, within-cohort association analyses, meta-analyses of discovery and validation stages, stratified analyses by sex and BMI, identification of eSNPs and nsSNPs, metabolomic and lipidomic analyses, CNV analyses, pathway analyses, analyses for non-European ancestries, association of a risk score with hypertension and cardiovascular disease, estimation of numbers of undiscovered variants, measurement of natriuretic peptides, and brief literature reviews and GWAS database lookups of all validated BP loci.
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![Genome-wide --log~10~ *P*-value plots and effects for significant loci.\
Genome-wide --log~10~ *P-*value plots are shown for systolic (SBP: panel a) and diastolic (DBP: panel b). SNPs within loci reaching genome-wide significance are labeled in red for SBP and blue for DBP (±2.5Mb of lowest *P*-value) and lowest *P-*values in the initial genome-wide analysis as well as the results of analysis including validation data are labeled separately. The lowest *P-*values in the initial GWAS are denoted as an X. The range of different sample sizes in the final meta-analysis including the validation data are indicated as: circle (96--140k), triangle (\>140--180k), and diamond (\>180--220k). SNPs near unconfirmed loci are in black. The horizontal dotted line is *P*=2.5 × 10^−8^. Panel c shows the effect size estimates and 95% confidence bars per BP-increasing allele of the 29 significant variants for SBP (red) and DBP (blue). Effect sizes are expressed in mmHg/allele. GUCY = *GUCY1A3-GUCY1B3*.](nihms314865f1){#F1}

###### Summary association results for 29 BP SNPs

Summary association statistics, based on combined discovery and follow-up data, for 29 independent SNPs in individuals of European ancestry are shown. New genome-wide significant findings (17 SNPs) are presented in the top half of the table, data on 12 previously published signals are presented in the lower half.

  Locus                    Index SNP    Chr   Position      CA/NCA   CAF    nsSNP   eSNP     SBP      DBP                                          HTN                                                                                                                                                                                                              
  ------------------------ ------------ ----- ------------- -------- ------ ------- -------- -------- -------------------------------------------- ------------------------------------------------------------------------ -------- -------------------------------------------- ------------------------------------------------------------------------ -------- --------------------------------------------
  ***MOV10***              rs2932538    1     113,018,066   G/A      0.75   Y(p)    Y(p)     0.388    1.2[\*](#TFN2){ref-type="table-fn"}10^−9^    +/+/−                                                                    0.24     9.9[\*](#TFN2){ref-type="table-fn"}10^−10^   +/+[\*](#TFN2){ref-type="table-fn"}/−                                    0.049    2.9[\*](#TFN2){ref-type="table-fn"}10^−7^
                                                                                                                                                                                                                                                                                                                                                                    
  ***SLC4A7***             rs13082711   3     27,512,913    T/C      0.78   Y(p)    Y(p)     −0.315   1.5[\*](#TFN2){ref-type="table-fn"}10^−6^    −/−/+                                                                    −0.238   3.8[\*](#TFN2){ref-type="table-fn"}10^−9^    −/−/+                                                                    −0.035   3.6[\*](#TFN2){ref-type="table-fn"}10^−4^
                                                                                                                                                                                                                                                                                                                                                                    
  ***MECOM***              rs419076     3     170,583,580   T/C      0.47   \-      \-       0.409    1.8[\*](#TFN2){ref-type="table-fn"}10^−13^   +/+/+                                                                    0.241    2.1[\*](#TFN2){ref-type="table-fn"}10^−12^   +/+/−                                                                    0.031    3.1[\*](#TFN2){ref-type="table-fn"}10^−4^
                                                                                                                                                                                                                                                                                                                                                                    
  ***SLC39A8***            rs13107325   4     103,407,732   T/C      0.05   Y       Y(+)     −0.981   3.3[\*](#TFN2){ref-type="table-fn"}10^−14^   ?/+/+                                                                    −0.684   2.3[\*](#TFN2){ref-type="table-fn"}10^−17^   ?/+/+                                                                    −0.105   4.9[\*](#TFN2){ref-type="table-fn"}10^−7^
                                                                                                                                                                                                                                                                                                                                                                    
  ***GUCY1A3-GUCY1B3***    rs13139571   4     156,864,963   C/A      0.76   \-      \-       0.321    1.2[\*](#TFN2){ref-type="table-fn"}10^−6^    +/−/+                                                                    0.26     2.2[\*](#TFN2){ref-type="table-fn"}10^−10^   +/−/+                                                                    0.042    2.5[\*](#TFN2){ref-type="table-fn"}10^−5^
                                                                                                                                                                                                                                                                                                                                                                    
  ***NPR3-C5orf23***       rs1173771    5     32,850,785    G/A      0.6    \-      \-       0.504    1.8[\*](#TFN2){ref-type="table-fn"}10^−16^   \+[\*](#TFN2){ref-type="table-fn"}/+/+                                   0.261    9.1[\*](#TFN2){ref-type="table-fn"}10^−12^   \+[\*](#TFN2){ref-type="table-fn"}/+/−                                   0.062    3.2[\*](#TFN2){ref-type="table-fn"}10^−10^
                                                                                                                                                                                                                                                                                                                                                                    
  ***EBF1***               rs11953630   5     157,777,980   T/C      0.37   \-      \-       −0.412   3.0[\*](#TFN2){ref-type="table-fn"}10^−11^   +/+/+                                                                    −0.281   3.8[\*](#TFN2){ref-type="table-fn"}10^−13^   +/+/+                                                                    −0.052   1.7[\*](#TFN2){ref-type="table-fn"}10^−7^
                                                                                                                                                                                                                                                                                                                                                                    
  ***HFE***                rs1799945    6     26,199,158    G/C      0.14   Y       \-       0.627    7.7[\*](#TFN2){ref-type="table-fn"}10^−12^   +/+/−                                                                    0.457    1.5[\*](#TFN2){ref-type="table-fn"}10^−15^   +/+/−                                                                    0.095    1.8[\*](#TFN2){ref-type="table-fn"}10^−10^
                                                                                                                                                                                                                                                                                                                                                                    
  ***BAT2-BAT5***          rs805303     6     31,724,345    G/A      0.61   Y(p)    Y(+)     0.376    1.5[\*](#TFN2){ref-type="table-fn"}10^−11^   −/−/?                                                                    0.228    3.0[\*](#TFN2){ref-type="table-fn"}10^−11^   −/−/+                                                                    0.054    1.1[\*](#TFN2){ref-type="table-fn"}10^−10^
                                                                                                                                                                                                                                                                                                                                                                    
  ***CACNB2(5***′***)***   rs4373814    10    18,459,978    G/C      0.55   \-      \-       −0.373   4.8[\*](#TFN2){ref-type="table-fn"}10^−11^   +/+/−                                                                    −0.218   4.4[\*](#TFN2){ref-type="table-fn"}10^−10^   −/+/−                                                                    −0.046   8.5[\*](#TFN2){ref-type="table-fn"}10^−8^
                                                                                                                                                                                                                                                                                                                                                                    
  ***PLCE1***              rs932764     10    95,885,930    G/A      0.44   \-      \-       0.484    7.1[\*](#TFN2){ref-type="table-fn"}10^−16^   +/+/−                                                                    0.185    8.1[\*](#TFN2){ref-type="table-fn"}10^−7^    +/+/−                                                                    0.055    9.4[\*](#TFN2){ref-type="table-fn"}10^−9^
                                                                                                                                                                                                                                                                                                                                                                    
  ***ADM***                rs7129220    11    10,307,114    G/A      0.89   \-      \-       −0.619   3.0[\*](#TFN2){ref-type="table-fn"}10^−12^   ?/−/+                                                                    −0.299   6.4[\*](#TFN2){ref-type="table-fn"}10^−8^    ?/−/+                                                                    −0.044   1.1[\*](#TFN2){ref-type="table-fn"}10^−3^
                                                                                                                                                                                                                                                                                                                                                                    
  ***FLJ32810-TMEM133***   rs633185     11    100,098,748   G/C      0.28   \-      \-       −0.565   1.2[\*](#TFN2){ref-type="table-fn"}10^−17^   \+[\*](#TFN2){ref-type="table-fn"}/+/+                                   −0.328   2.0[\*](#TFN2){ref-type="table-fn"}10^−15^   \+[\*](#TFN2){ref-type="table-fn"}/+/−                                   −0.07    5.4[\*](#TFN2){ref-type="table-fn"}10^−11^
                                                                                                                                                                                                                                                                                                                                                                    
  ***FURIN-FES***          rs2521501    15    89,238,392    T/A      0.31   \-      Y(−)     0.65     5.2[\*](#TFN2){ref-type="table-fn"}10^−19^   \+[\*](#TFN2){ref-type="table-fn"}/+/+                                   0.359    1.9[\*](#TFN2){ref-type="table-fn"}10^−15^   \+[\*](#TFN2){ref-type="table-fn"}/+/+                                   0.059    7.0[\*](#TFN2){ref-type="table-fn"}10^−7^
                                                                                                                                                                                                                                                                                                                                                                    
  ***GOSR2***              rs17608766   17    42,368,270    T/C      0.86   \-      Y(+)     −0.556   1.1[\*](#TFN2){ref-type="table-fn"}10^−10^   +/−/+                                                                    −0.129   0.017                                        +/−/+                                                                    −0.025   0.08
                                                                                                                                                                                                                                                                                                                                                                    
  ***JAG1***               rs1327235    20    10,917,030    G/A      0.46   \-      \-       0.34     1.9[\*](#TFN2){ref-type="table-fn"}10^−8^    \+[\*](#TFN2){ref-type="table-fn"}/+/+                                   0.302    1.4[\*](#TFN2){ref-type="table-fn"}10^−15^   \+[\*](#TFN2){ref-type="table-fn"}/+[\*](#TFN2){ref-type="table-fn"}/+   0.034    4.6[\*](#TFN2){ref-type="table-fn"}10^−4^
                                                                                                                                                                                                                                                                                                                                                                    
  ***GNAS-EDN3***          rs6015450    20    57,184,512    G/A      0.12   Y(p)    \-       0.896    3.9[\*](#TFN2){ref-type="table-fn"}10^−23^   ?/+/+                                                                    0.557    5.6[\*](#TFN2){ref-type="table-fn"}10^−23^   ?/+[\*](#TFN2){ref-type="table-fn"}/+                                    0.11     4.2[\*](#TFN2){ref-type="table-fn"}10^−14^
                                                                                                                                                                                                                                                                                                                                                                    
  ***MTHFR-NPPB***         rs17367504   1     11,785,365    G/A      0.15   \-      Y(−/r)   −0.903   8.7[\*](#TFN2){ref-type="table-fn"}10^−22^   +/+/+                                                                    −0.547   3.5[\*](#TFN2){ref-type="table-fn"}10^−19^   +/+/+                                                                    −0.103   2.3[\*](#TFN2){ref-type="table-fn"}10^−10^
                                                                                                                                                                                                                                                                                                                                                                    
  ***ULK4***               rs3774372    3     41,852,418    T/C      0.83   Y       Y(r/p)   −0.067   0.39                                         −/−/+                                                                    −0.367   9.0[\*](#TFN2){ref-type="table-fn"}10^−14^   +/+/+                                                                    −0.017   0.18
                                                                                                                                                                                                                                                                                                                                                                    
  ***FGF5***               rs1458038    4     81,383,747    T/C      0.29   \-      \-       0.706    1.5[\*](#TFN2){ref-type="table-fn"}10^−23^   \+[\*](#TFN2){ref-type="table-fn"}/+/+                                   0.457    8.5[\*](#TFN2){ref-type="table-fn"}10^−25^   \+[\*](#TFN2){ref-type="table-fn"}/+[\*](#TFN2){ref-type="table-fn"}/+   0.072    1.9[\*](#TFN2){ref-type="table-fn"}10^−7^
                                                                                                                                                                                                                                                                                                                                                                    
  ***CACNB2(3***′***)***   rs1813353    10    18,747,454    T/C      0.68   \-      \-       0.569    2.6[\*](#TFN2){ref-type="table-fn"}10^−12^   +/+/+                                                                    0.415    2.3[\*](#TFN2){ref-type="table-fn"}10^−15^   +/+/+                                                                    0.078    6.2[\*](#TFN2){ref-type="table-fn"}10^−10^
                                                                                                                                                                                                                                                                                                                                                                    
  ***C10orf107***          rs4590817    10    63,137,559    G/C      0.84   \-      Y(r)     0.646    4.0[\*](#TFN2){ref-type="table-fn"}10^−12^   −/+/−                                                                    0.419    1.3[\*](#TFN2){ref-type="table-fn"}10^−12^   −/−/−                                                                    0.096    9.8[\*](#TFN2){ref-type="table-fn"}10^−9^
                                                                                                                                                                                                                                                                                                                                                                    
  ***CYP17A1-NT5C2***      rs11191548   10    104,836,168   T/C      0.91   \-      Y(−)     1.095    6.9[\*](#TFN2){ref-type="table-fn"}10^−26^   \+[\*](#TFN2){ref-type="table-fn"}/+[\*](#TFN2){ref-type="table-fn"}/+   0.464    9.4[\*](#TFN2){ref-type="table-fn"}10^−13^   \+[\*](#TFN2){ref-type="table-fn"}/+[\*](#TFN2){ref-type="table-fn"}/+   0.097    1.4[\*](#TFN2){ref-type="table-fn"}10^−5^
                                                                                                                                                                                                                                                                                                                                                                    
  ***PLEKHA7***            rs381815     11    16,858,844    T/C      0.26   \-      \-       0.575    5.3[\*](#TFN2){ref-type="table-fn"}10^−11^   \+[\*](#TFN2){ref-type="table-fn"}/+/+                                   0.348    5.3[\*](#TFN2){ref-type="table-fn"}10^−10^   \+[\*](#TFN2){ref-type="table-fn"}/−/+                                   0.062    3.4[\*](#TFN2){ref-type="table-fn"}10^−6^
                                                                                                                                                                                                                                                                                                                                                                    
  ***ATP2B1***             rs17249754   12    88,584,717    G/A      0.84   \-      \-       0.928    1.8[\*](#TFN2){ref-type="table-fn"}10^−18^   \+[\*](#TFN2){ref-type="table-fn"}/+[\*](#TFN2){ref-type="table-fn"}/−   0.522    1.2[\*](#TFN2){ref-type="table-fn"}10^−14^   \+[\*](#TFN2){ref-type="table-fn"}/+[\*](#TFN2){ref-type="table-fn"}/−   0.126    1.1[\*](#TFN2){ref-type="table-fn"}10^−14^
                                                                                                                                                                                                                                                                                                                                                                    
  ***SH2B3***              rs3184504    12    110,368,991   T/C      0.47   Y       Y(+)     0.598    3.8[\*](#TFN2){ref-type="table-fn"}10^−18^   −/−/+                                                                    0.448    3.6[\*](#TFN2){ref-type="table-fn"}10^−25^   −/−/+                                                                    0.056    2.6[\*](#TFN2){ref-type="table-fn"}10^−6^
                                                                                                                                                                                                                                                                                                                                                                    
  ***TBX5-TBX3***          rs10850411   12    113,872,179   T/C      0.7    \-      \-       0.354    5.4[\*](#TFN2){ref-type="table-fn"}10^−8^    −/+/−                                                                    0.253    5.4[\*](#TFN2){ref-type="table-fn"}10^−10^   −/−/−                                                                    0.045    5.2[\*](#TFN2){ref-type="table-fn"}10^−6^
                                                                                                                                                                                                                                                                                                                                                                    
  ***CYP1A1-ULK3***        rs1378942    15    72,864,420    C/A      0.35   \-      Y(+)     0.613    5.7[\*](#TFN2){ref-type="table-fn"}10^−23^   \+[\*](#TFN2){ref-type="table-fn"}/+/+                                   0.416    2.7[\*](#TFN2){ref-type="table-fn"}10^−26^   \+[\*](#TFN2){ref-type="table-fn"}/+/−                                   0.073    1.0[\*](#TFN2){ref-type="table-fn"}10^−8^
                                                                                                                                                                                                                                                                                                                                                                    
  ***ZNF652***             rs12940887   17    44,757,806    T/C      0.38   \-      Y(−)     0.362    1.8[\*](#TFN2){ref-type="table-fn"}10^−10^   +/−/+                                                                    0.27     2.3[\*](#TFN2){ref-type="table-fn"}10^−14^   +/−/+                                                                    0.046    1.2[\*](#TFN2){ref-type="table-fn"}10^−7^

Y indicates the BP index SNP is a nsSNP, Y(p) indicates a proxy SNP is a nsSNP. Y(+): indicatesBP index SNP is the strongest known eSNP for a transcript; Y(−): indicates BP index SNP is an eSNP but not strongest known eSNP for any transcript. Y(r): indicates BP index SNP is strongest known eSNP in a regional SNP-RTPCR experiment. Y(p): indicates a proxy SNP (r^2^ \> 0.8) to BP SNP is an eSNP but not the strongest known eSNP. Observed effect directions in East Asian (EA), South Asian (SA), and African (A) ancestry individuals are coded + or − if concordant or discordant with directions in European ancestry results;

denotes significance controlling the FDR at 5% over 58 tests per ancestry ([Supplementary Tables 5 and 12](#SD1){ref-type="supplementary-material"}). Effect size estimates (beta) correspond to mmHg per coded allele for SBP and DBP and ln(odds) per coded allele for HTN.

CA = coded allele; NCA = non-coded allele; CAF = coded allele frequency; ? denotes missing data. Genomic positions use NCBI Build 36 coordinates.

###### Genetic risk score and cardiovascular outcome association results

Association of genetic risk score (using all 29 SNPs at 28 loci, parameterised using the average of SBP and DBP effects \[=(SBP effect + DBP effect)/2\] from the discovery analysis), tested in results from other GWAS consortia.

  Phenotype                                       Source                                  Effect    SE                                           *P*-value      \# SNPs   Contrast top vs. bottom   N case/control or total                                       
  ----------------------------------------------- --------------------------------------- --------- -------- ----------------------------------- -------------- --------- ------------------------- ------------------------- ----------------------------------- ---------------
  SBP \[mmHg\]                                    WGHS                                    1.645     0.098    [(a)](#TFN4){ref-type="table-fn"}   6.5\*10^−63^   29        4.61                      5.77                      [(a)](#TFN4){ref-type="table-fn"}   23,294
                                                                                                                                                                                                                                                                  
  DBP \[mmHg\]                                    WGHS                                    1.057     0.067    [(a)](#TFN4){ref-type="table-fn"}   8.4\*10^−57^   29        2.96                      3.71                      [(a)](#TFN4){ref-type="table-fn"}   23,294
                                                                                                                                                                                                                                                                  
  Prevalent hypertension                          WGHS                                    0.211     0.018    [(b)](#TFN5){ref-type="table-fn"}   3.1\*10^−33^   29        1.80                      2.09                      [(b)](#TFN5){ref-type="table-fn"}   5,018/18,276
                                                                                                                                                                                                                                                                  
  Prevalent hypertension                          BRIGHT                                  0.287     0.031    [(b)](#TFN5){ref-type="table-fn"}   7.7\*10^−21^   29        2.23                      2.74                      [(b)](#TFN5){ref-type="table-fn"}   2,406/1,990
                                                                                                                                                                                                                                                                  
  **Dichotomous endpoints**                                                                                                                                                                                                                                       
  Incident heart failure                          CHARGE-HF                               0.035     0.021    [(c)](#TFN6){ref-type="table-fn"}   0.10           29        1.10                      1.13                      [(c)](#TFN6){ref-type="table-fn"}   2,526/18,400
                                                                                                                                                                                                                                                                  
  Incident stroke                                 NEURO-CHARGE                            0.103     0.028    [(c)](#TFN6){ref-type="table-fn"}   0.0002         28        1.34                      1.44                      [(c)](#TFN6){ref-type="table-fn"}   1,544/18,058
                                                                                                                                                                                                                                                                  
  Prevalent stroke                                UK-US Stroke Collaborative Group(SCG)   0.075     0.037    [(b)](#TFN5){ref-type="table-fn"}   0.05           29        1.23                      1.30                      [(b)](#TFN5){ref-type="table-fn"}   1,473/1,482
                                                                                                                                                                                                                                                                  
  Stroke (combined, incident and prevalent)       CHARGE & SCG                            NA        NA       NA                                  3.3\*10^−5^    NA        NA                        NA                        NA                                  3,017/19,540
                                                                                                                                                                                                                                                                  
  Prevalent CAD                                   CARDIoGRAM                              0.092     0.010    [(b)](#TFN5){ref-type="table-fn"}   1.6\*10^−19^   28        1.29                      1.38                      [(b)](#TFN5){ref-type="table-fn"}   22,233/64,726
                                                                                                                                                                                                                                                                  
  Prevalent CAD                                   C4D ProCARDIS                           0.132     0.022    [(b)](#TFN5){ref-type="table-fn"}   2.2\*10^−9^    29        1.45                      1.59                      [(b)](#TFN5){ref-type="table-fn"}   5,720/4,381
                                                                                                                                                                                                                                                                  
  Prevalent CAD                                   C4D HPS                                 0.083     0.027    [(b)](#TFN5){ref-type="table-fn"}   0.002          29        1.26                      1.34                      [(b)](#TFN5){ref-type="table-fn"}   2,704/2,804
                                                                                                                                                                                                                                                                  
  Prevalent CAD (combined)                        CARDIoGRAM & C4D                        0.100     0.009    [(b)](#TFN5){ref-type="table-fn"}   8.1\*10^−29^   29        1.32                      1.42                      [(b)](#TFN5){ref-type="table-fn"}   30,657/71,911
                                                                                                                                                                                                                                                                  
  Prevalent chronic kidney disease                CKDGen                                  0.014     0.015    [(b)](#TFN5){ref-type="table-fn"}   0.35           29        1.04                      1.05                      [(b)](#TFN5){ref-type="table-fn"}   5,807/61,286
                                                                                                                                                                                                                                                                  
  Prevalent microalbuminuria                      CKDGen                                  0.008     0.019    [(b)](#TFN5){ref-type="table-fn"}   0.68           29        1.02                      1.03                      [(b)](#TFN5){ref-type="table-fn"}   3,698/27,882
                                                                                                                                                                                                                                                                  
  **Continuous measures oftarget organ damage**                                                                                                                                                                                                                   
  Left ventricular mass \[g\]                     EchoGen                                 0.822     0.317    [(a)](#TFN4){ref-type="table-fn"}   0.01           29        2.30                      2.89                      [(a)](#TFN4){ref-type="table-fn"}   12,612
                                                                                                                                                                                                                                                                  
  Left ventricular wall thickness\[cm\]           EchoGen                                 0.009     0.002    [(a)](#TFN4){ref-type="table-fn"}   6.0\*10^−6^    29        0.03                      0.03                      [(a)](#TFN4){ref-type="table-fn"}   12,612
                                                                                                                                                                                                                                                                  
  Serum creatinine                                KidneyGen                               −0.001    0.001    [(d)](#TFN7){ref-type="table-fn"}   0.24           29        1.00                      1.00                      [(d)](#TFN7){ref-type="table-fn"}   23,812
                                                                                                                                                                                                                                                                  
  eGFR (4 parameter MDRD equation)                CKDGen                                  −0.0001   0.0009   [(d)](#TFN7){ref-type="table-fn"}   0.93           29        1.00                      1.00                      [(d)](#TFN7){ref-type="table-fn"}   67,093
                                                                                                                                                                                                                                                                  
  Urinary albumin/creatinine ratio                CKDGen                                  0.005     0.007    [(d)](#TFN7){ref-type="table-fn"}   0.43           29        1.01                      1.02                      [(d)](#TFN7){ref-type="table-fn"}   31,580

Units are the unit of phenotypic measurement, either per SD of genetic risk score, or as a difference between top/bottom quintiles or deciles.

Units are ln(odds) per SD of genetic risk score, or odds ratio between top/bottom quintiles or deciles.

Units are ln(hazard) per SD of genetic risk score, or hazard ratio between top/bottom quintiles or deciles.

Units are ln(phenotype) per SD of genetic risk score, or phenotypic ratio between top/bottom quintiles or deciles.
